Skip to main content

Disclaimer

You’re about to visit the U.S. Diasorin Infection Management site (us.diasorin.com/bacterialviral), intended exclusively for audiences in the United States.
By clicking the button below you confirm that you are aware of entering the U.S site

Go to US site

If you prefer to continue browsing the international (non-U.S.) Diasorin website,
click the button below.

Go to INT Site

Section for healthcare professionals and other qualified operators only. This section contains information about in vitro diagnostic medical devices and is intended exclusively for healthcare professionals and other qualified operators under the applicable rules. By proceeding, you declare that you are a healthcare professional or an equivalent qualified operator and acknowledge that these contents are not intended for the general public.

Learning Library

Find all published Papers, Posters, and Abstracts

Featured

From Diagnostic Uncertainty to Whole-System Efficiency

Sepsis and severe infections place strain on emergency departments and inpatient capacity. Overcrowding, prolonged boarding, and resource strain create downstream operational and financial pressure.

See the Story
featured

Papers, Posters, and Abstracts

Paper
Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomized study

Stolz et al. | European Respiratory Journal

Discover more
Paper
Performance of Procalcitonin for the Early Identification of Sepsis in Patients with Elevated qSOFA Score at Emergency Admission

Bolanaki et al. | Journal of Clinical Medicine

Discover more
Abstract
Effect of Host-Protein Test (TRAIL/IP-10/CRP) on Antibiotic Prescription and Emergency Department or Urgent Care Center Return Visits: The JUNO Pilot Randomized Controlled Trial

Singer et al. | Academic Emergency Medicine

Discover more
Paper
A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections

Oved et al. | PLOS One

Discover more
Paper
Validation of a Novel Assay to Distinguish Bacterial and Viral Infections

Srugo et al. | Pediatrics

Discover more

Videos and Webinars

From Uncertainty to Clarity
Video

From Uncertainty to Clarity: Transforming Emergency Department Infection Diagnosis with Host Response Technology

Watch the video
A New FDA-Cleared Blood Test
Webinar

A New FDA-Cleared Blood Test

Watch the webinar
2023 AACC Annual Scientific Meeting + Clinical Lab Expo official vendor badge
Video

MeMed BV at AACC 2023 Presentation

Watch the video
Overcoming a major challenge in the ED
Video

Overcoming a major challenge in the ED

Watch the video

FAQs

MeMed BV measures three key immune response biomarkers:

  • TRAIL (TNF-Related Apoptosis-Inducing Ligand): The first FDA-cleared biomarker that rises with viral infections and decreases in bacterial infections.
  • IP-10 (Interferon Gamma-Induced Protein 10): A chemokine involved in immune cell activation and chemotaxis. Altered expression is linked to inflammation, infection, and immune dysregulation.
  • CRP (C-Reactive Protein): A well-known acute-phase protein that rises in both bacterial and viral infections, depending on the time since symptom onset.

A machine learning–derived algorithm combines these values into a single score that helps distinguish bacterial vs. viral infections within 7 days of symptom onset.

Yes. MeMed BV has a PLA CPT code 0315U. Consult CodeMap for additional details.

  • LIAISON® MeMed BV requires a serum sample.
  • MeMed Key accepts either serum or whole blood (whole blood option is FDA-cleared in the U.S.).

In the U.S.: For patients in ED or urgent care with suspected acute bacterial or viral infections, especially those with fever and symptoms ≤7 days.

Recommended Uses:

  • Antibiotic cessation in ICU patients
  • Lower respiratory tract infections (e.g., CAP, AECOPD)
  • Neonates over 34 weeks gestation, with caution in preterms

Not Recommended For:

  • Initiation of antibiotics
  • Mortality prediction in sepsis (despite FDA clearance)

In summary:

Not recommended in the ED for diagnosis or treatment initiation. 
Best used in ICU or hospitalized patients for guiding antibiotic discontinuation.

Yes. MeMed BV can identify bacterial immune responses even in the presence of viral co-infections, providing clearer guidance for treatment decisions.

The score reflects the likelihood of bacterial vs. viral infection, not disease severity.

Yes. MeMed BV is pathogen-agnostic, analyzing the host immune response instead of targeting specific pathogens. This makes it useful even for novel or unknown infectious agents.

Get in touch